CAJ | 학술논문

男性乳腺癌（male breast cancer，MBC）是一种少见的恶性疾病，有关治疗及预后的大型临床研究较少,目前对其多依据女性乳腺癌(female breast cancer，FBC)治疗。尽管男性乳腺癌与女性乳腺癌有较多相似之处，但二者仍存在较大差异，主要表现在对激素的依赖性及对激素治疗的敏感性不同。男性乳腺癌内分泌治疗的用药选择及用药时机仍存在较多争议，对常规内分泌药物耐药的男性乳腺癌患者的其他安全有效的治疗措施有待进一步研究。本文将就近年来男性乳腺癌药物治疗方面的研究进展进行综述，为临床治疗提供参考。
남성유선암（male breast cancer，MBC）시일충소견적악성질병，유관치료급예후적대형림상연구교소,목전대기다의거녀성유선암(female breast cancer，FBC)치료。진관남성유선암여녀성유선암유교다상사지처，단이자잉존재교대차이，주요표현재대격소적의뢰성급대격소치료적민감성불동。남성유선암내분비치료적용약선택급용약시궤잉존재교다쟁의，대상규내분비약물내약적남성유선암환자적기타안전유효적치료조시유대진일보연구。본문장취근년래남성유선암약물치료방면적연구진전진행종술，위림상치료제공삼고。
Male breast cancer (MBC) is an uncommon malignant disease, with few large-scale clinical studies on its treatment and prognosis. To date, MBC management is based on the guidelines for female breast cancer (FBC). Although MBC and FBC share many similarities, a few differences still exist between them, specifically in their hormonal dependence and sensitivity to endocrine ther-apy. Therefore, the drug selection and medication time remain controversial in the endocrine therapy of MBC. Furthermore, other safe and effective measures for MBC patients who are resistant to traditional endocrine therapy deserve further study. This review summariz-es recent major advances in MBC drug treatments, which intends to provide a reference for clinical treatment.